Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53

Cancer Biology and Therapy

Volumn 14, Issue 6, 2013, Pages 511-520

  Bai, Nan ^a   Zhang, Chunyan ^a   Liang, Ning ^a   Zhang, Zhuhong ^a   Chang, Antao ^a   Yin, Jing ^a   Li, Zongjin ^a   Li, Na ^a   Tan, Xiaoyue ^a   Luo, Na ^a   Luo, Yunping ^e   Xiang, Rong ^a   Li, Xiru ^d   Reisfeld, Ralph A ^b   Stupack, Dwayne ^c   Lv, Dan ^a,c   Liu, Chenghu ^a  

^a NANKAI UNIVERSITY   (China)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e Department of Immunology Beijing Union Medical school ^*  (China)

Author keywords

Hepatocellular carcinoma; P53; YAP

Indexed keywords

PEPTIDES AND PROTEINS; PROTEIN P53; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TP53 PROTEIN, HUMAN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL STRAIN HEPG2; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; PROTEIN BINDING; PROTEIN FUNCTION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER; LIVER TUMOR; METABOLISM; PHYSIOLOGY; PROMOTER REGION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER; LIVER NEOPLASMS; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879139034     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.24345     Document Type: Article

References (40)

1. Trinchet JC, Beaugrand M. Hepatocellular carcinoma: treatment with arterial chemo-embolization. Presse Med 1994; 23:831-3; PMID:7937602.
2. Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008; 20:638-46; PMID:18955139; http://dx.doi.org/10.1016/j.ceb.2008.10.001.
3. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22:1962-71; PMID:18579750; http://dx.doi.org/10.1101/gad.1664408.
4. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283:5496-509; PMID:18158288; http://dx.doi.org/10.1074/jbc. M709037200.
5. Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M, et al. Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 1995; 270:14733-41; PMID:7782338; http://dx.doi.org/10.1074/jbc.270.24.14733.
6. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001; 15:1229-41; PMID:11358867; http://dx.doi.org/10.1101/gad.888601.
7. Dobbelstein M, Strano S, Roth J, Blandino G. p73-induced apoptosis: a question of compartments and cooperation. Biochem Biophys Res Commun 2005; 331:688-93; PMID:15865923; http://dx.doi.org/10.1016/j.bbrc.2005.03.155.
8. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11:11-23; PMID:12535517; http://dx.doi.org/10.1016/S1097-2765(02)00776-1.
9. Danovi SA, Rossi M, Gudmundsdottir K, Yuan M, Melino G, Basu S. Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death Differ 2008; 15:217-9; PMID:17823615; http://dx.doi.org/ 10.1038/sj.cdd.4402226.
10. Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, Hong W, et al. Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev 2010; 24:290-300; PMID:20123908; http://dx.doi.org/10.1101/gad.1865310.
11. Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, et al. Structural insights into the YAP and TEAD complex. Genes Dev 2010; 24:235-40; PMID:20123905; http://dx.doi.org/10.1101/gad.1865810.
12. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 2009; 284:14347-58; PMID:19324876; http://dx.doi.org/10.1074/jbc.M901568200.
13. Zaidi SK, Sullivan AJ, Medina R, Ito Y, van Wijnen AJ, Stein JL, et al. Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 2004; 23:790-9; PMID:14765127; http://dx.doi.org/10.1038/sj.emboj.7600073.
14. Hong JH, Yaffe MB. TAZ: a beta-catenin-like molecule that regulates mesenchymal stem cell differentiation. Cell Cycle 2006; 5:176-9; PMID:16397409; http://dx.doi.org/10.4161/cc.5.2.2362.
15. Webb C, Upadhyay A, Giuntini F, Eggleston I, Furutani-Seiki M, Ishima R, et al. Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway. Biochemistry 2011; 50:3300-9; PMID:21417403; http://dx.doi.org/10.1021/bi2001888.
16. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278:33334-41; PMID:12807903; http://dx.doi.org/10.1074/jbc. M305597200.
17. Ehsanian R, Brown M, Lu H, Yang XP, Pattatheyil A, Yan B, et al. YAP dysregulation by phosphorylation or ΔNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 2010; 29:6160-71; PMID:20729916; http://dx.doi.org/10.1038/onc.2010. 339.
18. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005; 18:447-59; PMID:15893728; http://dx.doi.org/10.1016/j.molcel.2005.04.008.
19. Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011; 2011:603925; PMID:21188172; http://dx.doi.org/10.1155/2011/603925.
20. Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011; 2011:978312; PMID:21765642; http://dx.doi.org/10.1155/2011/978312.
21. Azizi B, Ziaei A, Fuchsluger T, Schmedt T, Chen Y, Jurkunas UV. p53-regulated increase in oxidativestress-induced apoptosis in Fuchs endothelial corneal dystrophy: a native tissue model. Invest Ophthalmol Vis Sci 2011; 52:9291-7; PMID:22064994; http://dx.doi.org/10.1167/iovs.11-8312.
22. Li M, He Y, Feng X, Huang J. Genome-wide studies of the transcriptional regulation by p53. Biochim Biophys Acta 2012; 1819:684-7; PMID:22348878; http://dx.doi.org/10.1016/j.bbagrm.2012.02.002.
23. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012; 119:3668-83; PMID:22275381; http://dx.doi.org/10.1182/ blood-2011-11-366062.
24. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21:2747-61; PMID:17974916; http://dx.doi.org/10.1101/gad.1602907.
25. Kowalik MA, Saliba C, Pibiri M, Perra A, Ledda-Columbano GM, Sarotto I, et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011; 53:2086-96; PMID:21391223; http://dx.doi.org/10.1002/hep.24289.
26. Avruch J, Zhou D, Bardeesy N. YAP oncogene overexpression supercharges colon cancer proliferation. Cell Cycle 2012; 11:1090-6; PMID:22356765; http://dx.doi.org/10.4161/cc.11.6.19453.
27. Yu LL, Dai N, Yu HG, Sun LM, Si JM. Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells. Oncol Rep 2010; 24:113-9; PMID:20514451; http://dx.doi.org/10.3892/or-00000835.
28. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009; 284:26533-46; PMID:19633292; http://dx.doi.org/10.1074/jbc.M109.027466.
29. Knapp P, Baranowski M, Knapp M, Zabielski P, Błachnio-Zabielska AU, Górski J. Altered sphingolipid metabolism in human endometrial cancer. Prostaglandins Other Lipid Mediat 2010; 92:62-6; PMID:20226264; http://dx.doi.org/10.1016/j.prostaglandins. 2010.03.002.
30. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009; 8:809-20; PMID:19372554; http://dx.doi.org/10.1158/1535-7163. MCT-08-1096.
31. Fu S, Hu W, Kavanagh JJ, Bast RC Jr. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets 2006; 10:77-85; PMID:16441230; http://dx.doi.org/10.1517/14728222.10.1.77.
32. Liu ZF, Wang Q, Yang SJ. The colocalized relationship between p53 mutants 249M, 273H and hsp70 in HepG2 cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009; 25:296-8; PMID:19351493.
33. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-13; PMID:9022073; http://dx.doi.org/10.1172/JCI119174.
34. Zhao B, Kim J, Ye X, Lai ZC, Guan KL. Both TEADbinding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res 2009; 69:1089-98; PMID:19141641; http://dx.doi.org/10.1158/0008-5472.CAN-08-2997.
35. Zhang X, Grusche FA, Harvey KF. Control of tissue growth and cell transformation by the Salvador/Warts/Hippo pathway. PLoS One 2012; 7:e31994; PMID:22359650; http://dx.doi.org/10.1371/journal. pone.0031994.
36. Bodó A, Bakos E, Szeri F, Váradi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 2003; 140-141:133-43; PMID:12676459; http://dx.doi.org/10.1016/S0378- 4274(02)00497-6.
37. Wang K, Degerny C, Xu M, Yang XJ. YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol 2009; 87:77-91; PMID:19234525; http://dx.doi.org/10.1139/O08-114.
38. Zeng Q, Hong W. The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008; 13:188-92; PMID:18328423; http://dx.doi.org/10.1016/j.ccr.2008.02.011.
39. Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T, et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 2008; 15:1752-9; PMID:18617895; http://dx.doi.org/10.1038/cdd.2008. 108.
40. Yuan M, Luong P, Hudson C, Gudmundsdottir K, Basu S. c-Abl phosphorylation of ΔNp63α is critical for cell viability. Cell Death Dis 2010; 1:e16; PMID:21364617; http://dx.doi.org/10.1038/cddis.2009.15.